Literature DB >> 6982501

HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease.

E Schrumpf, O Fausa, O Førre, J H Dobloug, S Ritland, E Thorsby.   

Abstract

Serologic HLA typing was carried out in 20 patients with ulcerative colitis (UC) combined with hepatobiliary disease, in 34 UC patients without hepatobiliary disease, and in control subjects. Association with HLA-B8 and -DR3 was found in both groups of patients. HLA-B8 was found in 80% of patients with combined disease (p less than 0.0005 vs. controls; relative risk (RR), 12.0), whereas 32% of the patients with UC without hepatobiliary disease were HLA-B8-positive (not significant vs. controls). Concomitantly, HLA-DR3 was found in 70% of patients with combined UC and hepatobiliary disease (p less than 0.0005 vs. controls; RR 9.95) and in 35% of UC patients without hepatobiliary disease (p less than 0.05 vs. controls; RR, 2.33). HLA-B8 was found more frequently in UC patients with than without hepatobiliary disease (p less than 0.001; RR, 8.36), as was the case with HLA-DR3 (p less than 0.025; RR, 4.28). No indications of defects in immunoregulatory lymphocytes (T gamma and T mu cells) which could explain hyperactivity in the immune system were observed in the patients with combined UC and hepatobiliary disease. The present study gives support to the theory that UC and, particularly, UC combined with hepatobiliary lesion may be autoimmune diseases with a genetic predisposition.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6982501     DOI: 10.3109/00365528209182038

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  49 in total

Review 1.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations.

Authors:  Christopher L Bowlus; Chin-Shang Li; Tom H Karlsen; Benedicte A Lie; Carlo Selmi
Journal:  Liver Transpl       Date:  2010-11       Impact factor: 5.799

Review 3.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

Review 4.  Immunopathogenesis of primary sclerosing cholangitis.

Authors:  Joy Worthington; Sue Cullen; Roger Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

5.  HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis.

Authors:  H Zetterquist; U Broomé; K Einarsson; O Olerup
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

Review 6.  Genetic epidemiology of primary sclerosing cholangitis.

Authors:  Tom-H Karlsen; Erik Schrumpf; Kirsten-Muri Boberg
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

7.  Suppressor T-cell deficiency in primary sclerosing cholangitis. Case and family study.

Authors:  A E Kilby; E L Krawitt; R J Albertini; B F Chastenay; A John
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

Review 8.  Etiopathogenesis of primary sclerosing cholangitis.

Authors:  Roger Chapman; Sue Cullen
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 9.  Immunological aspects of liver disease.

Authors:  A L Eddleston; P T Donaldson; J E Hegarty; B D Reed
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

10.  Crohn disease with sclerosing cholangitis and liver cirrhosis in adolescence.

Authors:  G P Ramelli; O Tönz; A Zimmermann; M J Lentze
Journal:  Eur J Pediatr       Date:  1991-06       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.